Streetbeat News

GUTS

Fractyl Health Inc.

Industry

Surgical and Medical Instrument Manufacturing

Open

2.14

Mkt cap

94M

Volume

380K

High

2.14

P/E Ratio

-1.43

52-wk high

14.50

Low

1.92

Div yield

N/A

52-wk low

1.74

Fractyl Health, Inc. (NASDAQ:GUTS) presented new preclinical data on its Rejuva pancreatic gene therapy program for obesity and type 2 diabetes at the American Diabetes Association's 84th Scientific Sessions. The study showed promising results in maintaining body composition and glycemia in a mouse model after semaglutide withdrawal.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:12 am

Fractyl Health, Inc. (NASDAQ:GUTS) presented new preclinical data showing that a single administration of its Rejuva pancreatic gene therapy reduced fat mass and improved glycemia in a diet-induced obesity mouse model. The data was presented at the American Diabetes Association's 84th Scientific Sessions and highlighted as one of the President's Select Abstracts.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2024 | 6:35 pm

The article highlights the performance of 12 health care stocks during Thursday's after-market session. Notable gainers include Venus Concept (VERO), Cyclacel Pharmaceuticals (CYCC), and Applied DNA Sciences (APDN). Significant losers include Biomea Fusion (BMEA), Tevogen Bio Holdings (TVGN), and Bright Green (BGXX).

Portfolio Pulse from Benzinga Insights

June 06, 2024 | 8:31 pm

Fractyl Health, Inc. (NASDAQ:GUTS) presented preclinical data from its Rejuva pancreatic gene therapy program at Digestive Disease Week 2024, focusing on a single-administration GLP-1 therapy for obesity and type 2 diabetes.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:04 am

Fractyl Health (NASDAQ:GUTS) reported a significant improvement in its Q1 2024 financial results with a GAAP EPS of $(0.17), up from $(7.87) YoY, and sales of $33,000, a 560% increase from $5,000 YoY.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 10:12 pm

Fractyl Health (NASDAQ:GUTS) reported a significant increase in sales for Q1, with $33.000 thousand in sales, marking a 560.00 percent increase from $5.000 thousand in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:06 pm

Cal-Maine Foods, Inc. (NASDAQ:CALM) shares rose by 8.3% in pre-market trading after reporting Q4 earnings of $3.00 per share, surpassing the consensus estimate of $2.46. Other stocks also showed significant movement in pre-market trading, with LAMF Global Ventures Corp. I (NASDAQ:LGVC) and Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) among the top gainers. Conversely, View, Inc. (NASDAQ:VIEW) and Acorda Therapeutics, Inc. (NASDAQ:ACOR) led the pre-market losers.

Portfolio Pulse from Avi Kapoor

April 03, 2024 | 12:11 pm

U.S. stock futures were lower, with Nasdaq futures down 0.2%. Intel Corporation shares fell 4.8% in pre-market trading after announcing a new financial framework for its foundry business. Other stocks like Mesoblast Limited, Fractyl Health, Inc., Nikola Corporation, Nuvation Bio Inc., Shinhan Financial Group Co., Ltd., XPeng Inc., and Li Auto Inc. also recorded losses in pre-market trading.

Portfolio Pulse from Avi Kapoor

April 03, 2024 | 9:36 am

Stryve Foods shares plummeted by 25% due to a significant fourth-quarter revenue miss. Other stocks experienced notable movements, with VivoPower International surging 315% after announcing a merger, and Acorda Therapeutics dropping 83.5% following a Chapter 11 bankruptcy filing. Various companies reported financial results, mergers, and other significant updates affecting their stock prices.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 5:23 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.